NHL Active Not Recruiting Phase 1 Trials for Rituximab (DB00073)

Also known as: Lymphomas: Non-Hodgkin / Non Hodgkin´s Lymphomas / Lymphoma, Non-Hodgkin (NHL) / NHL - Non-Hodgkin's Lymphoma / NHL (Non-Hodgkin Lymphoma) / Lymphoma,Non-Hodgkin / Non-Hodgkin's Disease / Lymphoma, Non-Hodgkin;Hodgkin Disease / Non Hodgkin Lymphoma / Non Hodgkin's Lymphoma / Lymphoma, Non Hodgkin / Non Hodgkin Lymphoma (NHL) / Non-Hodgkin / Non-Hodgkin's Lymphomas / Non-Hodgkin Lymphoma / Non-Hodgkin Lympoma / Non-Hodgkins Lymphoma (NHL) / Non-Hodgkin-Lymphoma / Lymphoma, Non-Hodgkin's / Non Hodgkins Lymphoma / Non-Hodgkin Lymphomas / Lymphoma, Non-Hodgkin / Non-Hodgkin's Lymphoma(NHL) / Non-Hodgkin's Lymphoma (NHL) / Lymphoma. Non-Hodgkin / Non-Hodgkin's Lymphoma / Non-Hodgkins Lymphoma / Lymphoma Non-Hodgkin / Non-Hodgkins's Lymphoma / Non-Hodgkin’s lymphoma / Lymphoma, Non-Hodgkins / Non-Hodgkins / Non-Hodgkin Lymphoma (NHL) / Non-Hodgkin's Lymphoma or Hodgkin's Disease / Lymphoma NOS / Histiocytosis X / Non-Hodgkin's lymphoma NOS / Lymphoma (non-Hodgkin's)

DBCOND0035368 (NHL)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02187133Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin LymphomaTreatment
NCT02594384A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL)Treatment
NCT02954406A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin LymphomaTreatment
NCT01594229A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's LymphomaTreatment
NCT00788684Safety Study of ABT-263 in Combination With Rituximab in Lymphoid CancersTreatment